Protagonist Therapeutics Inc (NASDAQ:PTGX) Given Average Rating of “Buy” by Brokerages

Shares of Protagonist Therapeutics Inc (NASDAQ:PTGX) have been assigned a consensus rating of “Buy” from the eight analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $18.20.

A number of brokerages have commented on PTGX. HC Wainwright set a $73.00 price objective on shares of Uniqure and gave the stock a “buy” rating in a research report on Monday, July 8th. Zacks Investment Research downgraded shares of ExlService from a “hold” rating to a “sell” rating in a research report on Wednesday. ValuEngine upgraded shares of VESTAS WIND SYS/ADR from a “hold” rating to a “buy” rating in a research report on Thursday, May 9th. Stifel Nicolaus upgraded shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating and upped their price objective for the stock from $11.00 to $17.00 in a research report on Wednesday, May 8th. Finally, BidaskClub upgraded shares of Misonix from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 3rd.

Several large investors have recently bought and sold shares of PTGX. D. E. Shaw & Co. Inc. grew its stake in shares of Protagonist Therapeutics by 75.5% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 19,645 shares of the company’s stock worth $132,000 after purchasing an additional 8,450 shares during the period. Bank of Montreal Can grew its stake in shares of Protagonist Therapeutics by 1,675.5% during the 1st quarter. Bank of Montreal Can now owns 11,026 shares of the company’s stock worth $139,000 after purchasing an additional 10,405 shares during the period. Bank of America Corp DE grew its stake in shares of Protagonist Therapeutics by 94.3% during the 4th quarter. Bank of America Corp DE now owns 26,419 shares of the company’s stock worth $178,000 after purchasing an additional 12,819 shares during the period. Northern Trust Corp grew its stake in shares of Protagonist Therapeutics by 17.2% during the 4th quarter. Northern Trust Corp now owns 34,624 shares of the company’s stock worth $234,000 after purchasing an additional 5,084 shares during the period. Finally, Tibra Equities Europe Ltd acquired a new position in shares of Protagonist Therapeutics during the 1st quarter worth $410,000. 64.40% of the stock is currently owned by institutional investors and hedge funds.



Protagonist Therapeutics stock traded down $0.42 during trading hours on Monday, reaching $13.23. 116,566 shares of the stock were exchanged, compared to its average volume of 303,070. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.02 and a current ratio of 5.02. Protagonist Therapeutics has a 52-week low of $5.49 and a 52-week high of $14.36. The company’s 50 day moving average price is $11.74.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.58) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.59) by $0.01. The company had revenue of $1.56 million during the quarter, compared to the consensus estimate of $2.50 million. Protagonist Therapeutics had a negative net margin of 209.02% and a negative return on equity of 40.78%. As a group, equities analysts predict that Protagonist Therapeutics will post -2.07 earnings per share for the current year.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD.

Featured Story: What is Depreciation?

Analyst Recommendations for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.